ストックスクリーナーアプリを入手
8.995
9.56%
0.785
前日終値:
$8.21
開ける：
$8.18
24時間の取引高:
79,632
Relative Volume:
0.59
時価総額：
$48.17M
収益：
-
当期純損益:
$-17.06M
株価収益率:
-0.1272
EPS:
-70.7173
ネットキャッシュフロー:
$-14.18M
1週間 パフォーマンス:
-16.34%
1か月 パフォーマンス:
-1.11%
6か月 パフォーマンス:
-85.83%
1年 パフォーマンス:
-98.61%
1日の値動き範囲:
$7.72
$9.30
1週間の範囲:
$7.72
$10.08
52週間の値動き範囲:
$7.72
$744.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
名前
Cns Pharmaceuticals Inc
セクター
電話
1-800-946-9185
住所
2100 WEST LOOP SOUTH, HOUSTON
CNSP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
8.975 | 48.17M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.72 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
566.92 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.70 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
589.68 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.66 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-12-28 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | 開始されました | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc (CNSP) 最新ニュース
What analysts say about CNS Pharmaceuticals Inc. stockFree Consultation - Autocar Professional
CNS Pharmaceuticals Inc. Stock Analysis and ForecastTremendous return rates - jammulinksnews.com
Is CNS Pharmaceuticals Inc. a good long term investmentSkyrocketing returns - jammulinksnews.com
Why CNS Pharmaceuticals Inc. stock attracts strong analyst attentionPrecision Entry Strategy - beatles.ru
CNS Pharmaceuticals Announces Reverse Stock Split - TipRanks
What drives CNS Pharmaceuticals Inc. stock priceFree Wealth Management Insights - jammulinksnews.com
CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference - 富途牛牛
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Featured In Virtual Investor Summer Spotlight Conference - Barchart.com
CNS Pharmaceuticals CEO Shares Brain Cancer Treatment Vision at Investor Conference | CNSP Stock News - Stock Titan
CNS Pharmaceuticals To Carry Out 1-for-12 Reverse Stock Split On July 22nd, 2025 - 富途牛牛
CNS Pharmaceuticals Implements 1-for-12 Reverse Stock Split to Consolidate Shares and Improve Market Position - AInvest
Published on: 2025-07-19 01:04:34 - jammulinksnews.com
CNS Pharmaceuticals (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22 - Barchart.com
CNS Pharmaceuticals announces 1-for-12 reverse stock split - Investing.com
CNS Pharmaceuticals announces 1-for-12 reverse stock split By Investing.com - Investing.com UK
Brain Cancer Drug Developer CNS Pharmaceuticals Announces 1:12 Reverse Split to Maintain Nasdaq Listing - Stock Titan
How CNS Pharmaceuticals Inc. stock performs during market volatility3x Growth Potential - Newser
CNS Pharmaceuticals Posts Investor Presentation on Brain Cancer - TipRanks
CNSP SEC FilingsCNS Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
What makes CNS Pharmaceuticals Inc. stock price move sharplySmart Money Trade Setups - Newser
Biohaven, Bexorg Partner to Accelerate CNS Drug Discovery Using Novel Whole-Brain Platform - Yahoo Finance
Jazz Looks To Block Avadel From Asking For Sleep Drug OK - Law360
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Lead Program In Virtual CEO Segment - Barchart.com
CNS Pharmaceuticals: TPI 287 Shows Potential in Treating CNS Tumors, CEO Discusses Recent Clinical Data at Virtual Investor CEO Connect Segment - AInvest
CNS Pharma CEO Shares Exclusive Insights on Novel Brain Cancer Treatment TPI 287 at Healthcare Leaders Meeting - Stock Titan
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Lead Program in Virtual CEO Segment - FinancialContent
CNS Pharmaceuticals (NASDAQ:CNSP) Shares Down 2% – Here’s What Happened - Defense World
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights GBM Treatment Insights In KOL Segment Featuring Dr. Erin Dunbar - Barchart.com
CNS Pharmaceuticals Inc. Sheds Light on GBM Treatment Advances in KOL Segment with Dr. Erin Dunbar - citybuzz -
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Featuring Dr. Erin Dunbar Discussing Glioblastoma Multiforme and Lead Product Candidate TPI 287 - AInvest
Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market - Investing.com
Revolutionary Nasal Drug Delivery System Could Transform Treatment of Opioid Overdose and Epilepsy - Stock Titan
Citadel Advisors LLC Takes Position in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - Defense World
Jane Street Group LLC Boosts Stake in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - Defense World
Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development - Yahoo Finance
CNS Pharmaceuticals (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit - Barchart.com
Cns Pharmaceuticals Inc (CNSP) 財務データ
収益
当期純利益
現金流量
EPS
3.24%
1.96%
大文字化:
|
ボリューム (24 時間):